These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 20444895)

  • 1. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.
    Lopez LA; Yang SJ; Hauser H; Exline CM; Haworth KG; Oldenburg J; Cannon PM
    J Virol; 2010 Jul; 84(14):7243-55. PubMed ID: 20444895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.
    Lopez LA; Yang SJ; Exline CM; Rengarajan S; Haworth KG; Cannon PM
    J Virol; 2012 May; 86(10):5467-80. PubMed ID: 22398279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
    Lucas TM; Janaka SK; Stephens EB; Johnson MC
    PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration.
    Gupta RK; Mlcochova P; Pelchen-Matthews A; Petit SJ; Mattiuzzo G; Pillay D; Takeuchi Y; Marsh M; Towers GJ
    Proc Natl Acad Sci U S A; 2009 Dec; 106(49):20889-94. PubMed ID: 19864625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
    Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
    PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
    Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
    Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
    Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
    PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
    Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
    J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin.
    Kühl A; Banning C; Marzi A; Votteler J; Steffen I; Bertram S; Glowacka I; Konrad A; Stürzl M; Guo JT; Schubert U; Feldmann H; Behrens G; Schindler M; Pöhlmann S
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S850-60. PubMed ID: 21987761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
    Vigan R; Neil SJ
    J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAML does not modulate tetherin-mediated restriction of HIV-1 particle release.
    Ali MS; Hammonds J; Ding L; Spearman P
    PLoS One; 2010 Feb; 5(2):e9005. PubMed ID: 20126395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
    Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
    J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
    Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
    Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.
    Gupta RK; Hué S; Schaller T; Verschoor E; Pillay D; Towers GJ
    PLoS Pathog; 2009 May; 5(5):e1000443. PubMed ID: 19461879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.
    Lim ES; Malik HS; Emerman M
    J Virol; 2010 Jul; 84(14):7124-34. PubMed ID: 20444900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
    Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
    PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
    Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA
    PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.
    Tokarev A; Skasko M; Fitzpatrick K; Guatelli J
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1197-210. PubMed ID: 19929170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vpu binds directly to tetherin and displaces it from nascent virions.
    McNatt MW; Zang T; Bieniasz PD
    PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.